These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25927917)

  • 1. Emerging, Non-PCV13 Serotypes 11A and 35B of Streptococcus pneumoniae Show High Potential for Biofilm Formation In Vitro.
    Domenech M; Damián D; Ardanuy C; Liñares J; Fenoll A; García E
    PLoS One; 2015; 10(4):e0125636. PubMed ID: 25927917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro biofilm formation by Streptococcus pneumoniae as a predictor of post-vaccination emerging serotypes colonizing the human nasopharynx.
    Domenech M; Araújo-Bazán L; García E; Moscoso M
    Environ Microbiol; 2014 Apr; 16(4):1193-201. PubMed ID: 24373136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in Streptococcus pneumoniae serotype distribution in invasive disease and nasopharyngeal carriage after the heptavalent pneumococcal conjugate vaccine introduction in Bogotá, Colombia.
    Parra EL; De La Hoz F; Díaz PL; Sanabria O; Realpe ME; Moreno J
    Vaccine; 2013 Aug; 31(37):4033-8. PubMed ID: 23680440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012-2014.
    Nakano S; Fujisawa T; Ito Y; Chang B; Suga S; Noguchi T; Yamamoto M; Matsumura Y; Nagao M; Takakura S; Ohnishi M; Ihara T; Ichiyama S
    Vaccine; 2016 Jan; 34(1):67-76. PubMed ID: 26602268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children.
    Varon E; Cohen R; Béchet S; Doit C; Levy C
    Vaccine; 2015 Nov; 33(46):6178-85. PubMed ID: 26476365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decline in Pneumococcal Nasopharyngeal Carriage of Vaccine Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Children in Atlanta, Georgia.
    Desai AP; Sharma D; Crispell EK; Baughman W; Thomas S; Tunali A; Sherwood L; Zmitrovich A; Jerris R; Satola SW; Beall B; Moore MR; Jain S; Farley MM
    Pediatr Infect Dis J; 2015 Nov; 34(11):1168-74. PubMed ID: 26226445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyamine transporter potABCD is required for virulence of encapsulated but not nonencapsulated Streptococcus pneumoniae.
    Pipkins HR; Bradshaw JL; Keller LE; Swiatlo E; McDaniel LS
    PLoS One; 2017; 12(6):e0179159. PubMed ID: 28586394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-invasive pneumococcal serotypes and antimicrobial susceptibilities in a paediatric hospital in the era of conjugate vaccines.
    McElligott M; Vickers I; Cafferkey M; Cunney R; Humphreys H
    Vaccine; 2014 Jun; 32(28):3495-500. PubMed ID: 24795223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.
    Sharma D; Baughman W; Holst A; Thomas S; Jackson D; da Gloria Carvalho M; Beall B; Satola S; Jerris R; Jain S; Farley MM; Nuorti JP
    Pediatr Infect Dis J; 2013 Feb; 32(2):e45-53. PubMed ID: 23080290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High invasiveness of pneumococcal serotypes included in the new generation of conjugate vaccines.
    del Amo E; Brotons P; Monsonis M; Triviño M; Iñigo M; Selva L; Sa-Leão R; Muñoz-Almagro C
    Clin Microbiol Infect; 2014 Jul; 20(7):684-9. PubMed ID: 24467648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nationwide population-based surveillance of invasive pneumococcal disease in Japanese children: Effects of the seven-valent pneumococcal conjugate vaccine.
    Suga S; Chang B; Asada K; Akeda H; Nishi J; Okada K; Wakiguchi H; Maeda A; Oda M; Ishiwada N; Saitoh A; Oishi T; Hosoya M; Togashi T; Oishi K; Ihara T
    Vaccine; 2015 Nov; 33(45):6054-60. PubMed ID: 26235372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction.
    Gladstone RA; Jefferies JM; Tocheva AS; Beard KR; Garley D; Chong WW; Bentley SD; Faust SN; Clarke SC
    Vaccine; 2015 Apr; 33(17):2015-21. PubMed ID: 25776920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structures of Capsular Polysaccharide Serotypes 35F and 35C of Streptococcus pneumoniae Determined by Nuclear Magnetic Resonance and Their Relation to Other Cross-Reactive Serotypes.
    Bush CA; Cisar JO; Yang J
    J Bacteriol; 2015 Sep; 197(17):2762-9. PubMed ID: 26055112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of pneumococcal carriage among day-care center attendees during the transition from the 7-valent to the higher-valent pneumococcal conjugate vaccines in Greece.
    Grivea IN; Priftis KN; Giotas A; Kotzia D; Tsantouli AG; Douros K; Michoula AN; Syrogiannopoulos GA
    Vaccine; 2014 Nov; 32(48):6513-20. PubMed ID: 25252194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in pneumococcal nasopharyngeal colonization among children with respiratory tract infections before and after use of the two new extended-valency pneumococcal conjugated vaccines.
    Ahn JG; Choi SY; Kim DS; Kim KH
    Infect Dis (Lond); 2015 Jun; 47(6):385-92. PubMed ID: 25712791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in asymptomatic nasopharyngeal colonization with streptococcus pneumoniae after introduction of the 13-valent pneumococcal conjugate vaccine in Calgary, Canada.
    Ricketson LJ; Wood ML; Vanderkooi OG; MacDonald JC; Martin IE; Demczuk WH; Kellner JD;
    Pediatr Infect Dis J; 2014 Jul; 33(7):724-30. PubMed ID: 24463806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotype distribution and antimicrobial susceptibilities of nasopharyngeal isolates of Streptococcus pneumoniae from healthy children in the 13-valent pneumococcal conjugate vaccine era.
    Zuccotti G; Mameli C; Daprai L; Garlaschi ML; Dilillo D; Bedogni G; Faccini M; Gramegna M; Torresani E; ; Ballerini E; Benincaso A; Bonvissuto M; Bricalli D; Brioschi M; Calloni CS; Camiletti MI; Colella G; De Angelis L; Decarlis S; Di Nello F; Dozzi M; Galli E; Gandini V; Giuliani MG; Laviola F; Loda B; Macedoni M; Mazzucchi E; Metta MG; Moscatiello A; Nannini P; Petruzzi M; Picicco D; Picciotti M; Pisanelli S; Porta N; Ramponi G; Redaelli F; Rubini R; Sala N; Saitta V; Scelza G; Tiso RM; Tomasetto M; Torcoletti M; Travaini M; Valentini M; Vessia C
    Vaccine; 2014 Jan; 32(5):527-34. PubMed ID: 24342249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of multidrug resistance, clonality and virulence in non-PCV-13 Streptococcus pneumoniae serotypes in Canada, 2011-13.
    Golden AR; Adam HJ; Gilmour MW; Baxter MR; Martin I; Nichol KA; Demczuk WH; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2015 Jul; 70(7):1960-4. PubMed ID: 25761605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden.
    Galanis I; Lindstrand A; Darenberg J; Browall S; Nannapaneni P; Sjöström K; Morfeldt E; Naucler P; Blennow M; Örtqvist Å; Henriques-Normark B
    Eur Respir J; 2016 Apr; 47(4):1208-18. PubMed ID: 26797033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.